The UK and US have established a major commercial pact that will ensure no tariffs on UK pharmaceutical shipments being sold in the US market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to increase funding on medicines through the National Health Service (NHS). This move guarantees that duties on these key products will stay at zero for a duration of 36 months.
This agreement comes after recent warnings to significantly raise tariffs on patented drug products, with increases mentioned up to 100%.
"This deal between the UK strengthens the international landscape for new treatments and brings much-needed fairness to transatlantic drug exports," a statement noted.
Trade Impact
Drugs constitute one of the Britain's largest goods shipped to the America, which is easily the biggest market for large companies like GSK and AstraZeneca.
Export figures show that in the one-year period leading up to September, the UK sold drugs totaling £11.1bn to the US. This figure represented nearly one-fifth of total UK exports in that period.
"This deal protects work, stimulates capital expenditure and paves the way for the UK to emerge as a global hub for biotech and pharma," a minister commented.
Specific British Pledges
The deal involves several specific pledges from the British government:
- Higher Cost Ceiling: The UK will increase the price threshold at which it judges new medicines to be too expensive by 25%.
- Increased NHS Spending: There is a goal to increase total NHS spending on medicines from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The sum manufacturers must refund to the NHS to stay within budget will be limited at fifteen percent. In the past, refunds topped twenty percent.
Industry Background
The deal follows a protracted row between the sector and the UK government over medicine costs and regulatory access.
The disagreement were intensified by arguments that American customers were paying significantly more for the same drugs than consumers in the other developed nations.
Recently, several major drug company projects in the UK have been halted or scrapped, while multi-billion-dollar expansions have been pledged toward American operations.
The Science Minister publicly accepted that the NHS needed to spend more on drugs, noting that its budget allocation on drugs had declined as a percentage of its resources over the previous ten-year period.
